Table 3.
Comparison of transarterial chemoembolization with radiofrequency ablation versus transarterial chemoembolization of patients with BCLC stage B hepatocellular carcinoma after propensity score matching
| Variable | TACE+RFA (n = 56) | TACE (n = 231) | P-value |
|---|---|---|---|
| Male | 42 (75.0) | 173 (74.9) | 0.987 |
| Age (years) | 64 (28–86) | 64 (29–91) | 0.672 |
| Smoking | 27 (47.4) | 113 (48.9) | 0.925 |
| Alcohol use | 23 (40.4) | 100 (43.3) | 0.763 |
| HBV positive | 32 (56.1) | 103 (44.6) | 0.091 |
| HCV positive | 21 (36.8) | 90 (39.0) | 0.085 |
| Total Bilirubin | 1.41 ± 0.67 | 1.34 ± 1.14 | 0.643 |
| INR | 1.10 ± 0.14 | 1.06 ± 0.12 | 0.060 |
| Cirrhosis | 43 (75.4) | 155 (67.1) | 0.160 |
| Child-Pugh class A | 43 (76.8) | 194 (84.0) | 0.203 |
| Tumor size | 5.5 ± 2.6 | 7.0 ± 3.8 | 0.062 |
| Tumor size≥5 cm | 25 (44.6) | 149 (64.5) | 0.053 |
| Tumor number (≥3) | 50 (89.3) | 178 (77.1) | 0.051 |
| AFP (ng/mL) ≥ 200 | 6 (10.7) | 50 (21.6) | 0.064 |
| Mortality | 34 (59.6) | 173 (74..9) | 0.034 |
| Follow up times (months) | 36 (3–95) | 22 (1–97) | < 0.0001 |
BCLC stage: Barcelona clinic liver cancer; SR Surgical resection; TACE Transcatheter arterial chemoembolization; RFA Radiofrequency ablation; HBV Hepatitis B virus; HCV Hepatitis C virus; AFP: INR International normalize ratio; Alpha-fetoprotein;